Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides
摘要:
An important goal in the development of polo-like kinase 1 (Plk1) polo-box domain (PBD) binding inhibitors is selectivity for Plk1 relative to Plk2 and Plk3. In our current work we show that Plk1 PBD selectivity can be significantly enhanced by modulating interactions within a previously discovered "cryptic pocket" and a more recently identified proximal "auxiliary pocket." Published by Elsevier Ltd.
A Noncoordinating Acid–Base Catalyst for the Mild and Nonreversible <i>tert</i>-Butylation of Alcohols and Phenols
作者:Keith R. Fandrick、Nitinchandra D. Patel、Suttipol Radomkit、Arindom Chatterjee、Stefan Braith、Daniel R. Fandrick、Carl A. Busacca、Chris H. Senanayake
DOI:10.1021/acs.joc.1c00193
日期:2021.3.19
A mild and nonreversible tert-butylation of alcohols and phenols can be achieved in high yields using the noncoordinating acid–base catalyst [bis(trifluoromethane)sulfonimide and 2,6-lutidine] with a tert-butylation reagent, tert-butyl 2,2,2-trichloroacetimidate. This method allows the use of substrates containing acid sensitive groups such as ketal, Boc, and boronate esters.
Role of Lewis and Brønsted acid sites in resorcinol <i>tert</i>-butylation over heteropolyacid-based catalysts
作者:Chiara Pezzotta、Vijaykumar S. Marakatti、Eric M. Gaigneaux
DOI:10.1039/d0cy01030h
日期:——
was performed to distinguish between Brønsted and Lewissites. The resorcinol conversion was correlated to the fraction of Brønstedsites present at the catalyst surface based on the total acidity. The results pointed out the importance of considering both Brønsted and Lewissites as active players in the mechanism of resorcinol alkylation: Lewissites have the role of adsorbing the substrate close to
Alkylation of resorcinol with tertiary butanol over zeolite catalysts: Shape selectivity vs acidity
作者:Vijaykumar S. Marakatti、Eric M. Gaigneaux
DOI:10.1016/j.catcom.2021.106291
日期:2021.4
of various zeolites such as H-ZSM-5, H-Y, H-beta, H-Mordenite in resorcinol alkylation with tertiary butanol demonstrated that pore characteristics have major influence on product selectivity, whereas acid strength and number of acid sites influenced resorcinol conversion. The passivation of external surface of H-beta zeolite by silylation and amine poisoning produced shape selectively O-alkylated
[EN] 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS<br/>[FR] COMPOSES 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE POUR LE TRAITEMENT DE LA TUBERCULOSE
申请人:OTSUKA PHARMA CO LTD
公开号:WO2005042542A1
公开(公告)日:2005-05-12
The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1)in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and -(CH2)nR2 may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring), (30)and R2 represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria.
The following compounds useful as VEGF receptor antagonists and having excellent physical properties are provided.
A carboxylic acid derivative represented by formula:
wherein ring A represents a benzene ring, a naphthalene ring, or the like; W represents a C1-5 alkylene group; Z represents a single bond or a phenylene group; R1 and R2 are the same or different and each represents a hydrogen atom, a halogen atom, a C1-5 alkyl group or a C1-10 alkoxy group; R3 represents a hydrogen atom, a halogen atom, a C1-12 alkyl group, a C2-5 alkynyl group, a trifluoromethyl group, an acetynyl group, a cyano group, a nitro group, -CH2-R6, -Y-R11, or the like; R4 represents a group represented by formula:
and
R5 represents a hydrogen atom or a C1-5 alkyl group, or a pharmaceutical acceptable salt of the derivative.